FUJIFILM Corporation will invest approximately $37 million in the pharmaceutical production site of its group company, Toyama Chemical Co., Ltd., to build a new manufacturing facility in Toyama prefecture, Japan.
At the facility, the company plans to manufacture liposome drugs utilizing proprietary technologies such as its anti-cancer agent FF-10832 for the use of clinical trials and commercial marketing. Construction of the new facility will begin in September 2018, and the facility is scheduled to begin operations in February 2020.
Liposome drugs contain drugs in artificially constructed vesicles made from the same organic phospholipids that make up cell and bio membranes. Currently, Fujifilm is harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated through the photographic film business to promote the research and development of liposome drugs that efficiently deliver drugs to the affected area and enhance efficacy. The company is also conducting research and development aiming for the early start of clinical trials on liposome drugs other than FF-10832.
The new facility will manufacture liposome drugs in compliance with Japan/U.S./Europe GMP standards. The facility will enable the stable production of highly reliable, high quality liposome drugs through the adoption of manufacturing equipment originally designed and developed using Fujifilm’s advanced production technologies and the installation of high containment facilities as well as the use of know-how of Toyama Chemical cultivated in the sterile production of injectable formulations. The facility will also feature advanced production systems using cutting-edge ICT technologies. This will enable the centralized control of the manufacturing process, quality assessment data, and facility operation data, as well as the control of use of raw materials and parts through electronic tags, to achieve efficient production operations.
The new facility will manufacture liposome drugs such as FF-10832 for use in the clinical studies and commercial marketing, ensuring the stable supply of high quality liposome drugs.